# Withanolide

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/withanolide
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Steroidal lactones, Ergostane-type steroids, Withania steroids, Ashwagandha steroids, Withanoside precursors, Solanaceae steroids

## Overview

Withanolides are a class of over 300 naturally occurring steroidal lactones derived primarily from Withania somnifera (ashwagandha), biosynthesized via the mevalonate pathway. Their primary bioactive mechanisms involve modulation of NF-κB signaling, Hsp90 inhibition, and binding to steroid hormone receptors, driving their [adaptogen](/ingredients/condition/stress)ic and [anti-inflammatory](/ingredients/condition/inflammation) properties.

## Health Benefits

• The research provided focuses on phytochemical characterization rather than clinical outcomes - no specific health benefits with evidence quality can be cited from these sources
• Biosynthetic pathway studies show withanolides are produced via the mevalonate pathway
• Over 300 distinct variants have been identified including withanolide A, D, withaferin A, and withanone
• Gene expression studies demonstrate HMGR-1 upregulation correlates with withanolide accumulation
• No clinical trials or health outcome data are present in the provided research

## Mechanism of Action

Withanolide A and withaferin A bind to the C-terminal domain of Hsp90, disrupting client protein stabilization and promoting proteasomal degradation of oncoproteins such as Akt and CDK4. Withaferin A also covalently binds to the IKKβ subunit of the IκB kinase complex, suppressing NF-κB nuclear translocation and downstream [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression including TNF-α and IL-6. Additionally, withanolides interact with glucocorticoid receptors and modulate [hypothalamic-pituitary-adrenal](/ingredients/condition/stress) axis activity, contributing to observed reductions in serum cortisol in human trials.

## Clinical Summary

Human clinical trials have focused predominantly on full-spectrum ashwagandha root extracts standardized to withanolide content (typically 2.5–5%) rather than isolated withanolide compounds, limiting direct attribution of effects. A 60-participant RCT (Chandrasekhar et al., 2012) using 300 mg twice-daily extract standardized to withanolides reported a 27.9% reduction in serum [cortisol](/ingredients/condition/stress) and significant improvements on the Perceived Stress Scale versus placebo. A separate 8-week RCT (n=57) demonstrated statistically significant improvements in [testosterone levels](/ingredients/condition/hormonal) and muscle recovery with withanolide-standardized extract versus placebo. Evidence quality for isolated withanolides in humans remains low, with most mechanistic data derived from in vitro and rodent models; large-scale phase II/III trials on purified withanolides are absent.

## Nutritional Profile

Withanolide is a bioactive steroidal lactone compound (C28 ergostane-type skeleton), not a conventional nutritional ingredient with macronutrients or micronutrients. Bioactive compound data: Steroidal lactone core structure with molecular formula typically C28H38O6 (withanolide A) to C28H32O6 (withaferin A) depending on variant; molecular weights ranging approximately 470–500 g/mol across 300+ identified variants. Key variants include Withanolide A (primary [immunomodulatory](/ingredients/condition/immune-support) form), Withanolide D, Withaferin A (most studied, potent bioactive), and Withanone. Concentrations in Withania somnifera root extract: Withanolides total 0.001–0.05% in raw root dry weight; standardized commercial extracts typically concentrated to 2.5–35% total withanolides. Withaferin A typically 0.0012–0.002% in raw root; Withanolide A approximately 0.001–0.003% dry weight. Biosynthetic origin: mevalonate pathway (terpenoid biosynthesis), classifying these as triterpenoid-derived steroidal lactones. Bioavailability notes: Oral bioavailability is moderate; lipophilic nature facilitates intestinal absorption but first-pass hepatic [metabolism](/ingredients/condition/weight-management) is significant. Co-administration with piperine or lipid-based delivery systems reported to enhance absorption. Half-life data limited in humans. No caloric, protein, fat, or carbohydrate contribution as an isolated compound. Micronutrient content: negligible as an isolated phytochemical.

## Dosage & Preparation

No clinically studied dosage ranges are available in the provided research. The sources indicate total withanolide content in plant material ranges from 0.001-0.5% of dry weight, but do not specify standardized extract doses or clinical dosing protocols. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Ashwagandha extracts standardized to withanolides are generally well-tolerated at doses of 300–600 mg daily, with the most commonly reported adverse effects being mild gastrointestinal upset, loose stools, and drowsiness. Withanolides may potentiate the effects of sedative medications (benzodiazepines, barbiturates) and [thyroid](/ingredients/condition/hormonal) hormone therapy, as preclinical and limited clinical data suggest thyroid-stimulating activity including elevated T3 and T4 levels. Withaferin A exhibits potent cytotoxic activity in vitro and animal models, raising theoretical concerns about concurrent use with immunosuppressants or chemotherapy agents, though no confirmed clinical interactions have been established. Withanolide-containing supplements are contraindicated in pregnancy due to historical use as an abortifacient and evidence of uterotonic effects in animal studies, and safety during lactation has not been established.

## Scientific Research

The provided research dossier contains no clinical trials, randomized controlled trials, or meta-analyses evaluating withanolide efficacy for health conditions. The available sources focus exclusively on phytochemical characterization, biosynthetic pathways, and structural identification rather than clinical outcomes or PMIDs.

## Historical & Cultural Context

The research confirms Withania somnifera is described as 'a medicinal plant of immense repute' and 'a multipurpose medicinal plant,' but provides no specific details about traditional applications, duration of historical use, or cultural contexts.

## Synergistic Combinations

Insufficient data in provided research to determine synergistic ingredients

## Frequently Asked Questions

### What is the difference between withanolides and withaferin A?

Withanolides are the broad class of over 300 steroidal lactone compounds found in Withania somnifera, while withaferin A is the single most studied individual withanolide within that class. Withaferin A is characterized by a specific C-28 steroidal skeleton with an α,β-unsaturated carbonyl group that enables covalent binding to target proteins like Hsp90 and vimentin, making it the primary subject of anticancer and anti-inflammatory mechanistic research.

### How much withanolide content should an ashwagandha supplement contain?

Clinical trials showing significant effects on cortisol and stress markers have typically used extracts standardized to 2.5–5% total withanolides, with daily doses of 300–600 mg, equating to roughly 7.5–30 mg of withanolides per day. KSM-66 and Sensoril are two commercially validated extracts with published standardization data; consumers should verify that the supplement specifies the percentage of withanolides on the label rather than relying solely on root powder weight.

### Can withanolides affect thyroid hormone levels?

Preclinical studies and a small human trial (n=32, Sharma et al., 2018) suggest withanolide-standardized ashwagandha root extract can significantly increase serum T3 and T4 levels, with the human study reporting a statistically significant elevation after 8 weeks. This makes withanolide-containing supplements potentially problematic for individuals with hyperthyroidism or those on levothyroxine or antithyroid medications, and thyroid function should be monitored if use is initiated.

### Are withanolides safe for daily long-term use?

Safety data from published trials extends to approximately 8–12 weeks of daily use with standardized extracts, during which adverse events were comparable to placebo at doses up to 600 mg/day. Long-term safety data beyond 3 months for withanolide-standardized extracts is limited, and isolated cases of hepatotoxicity have been reported with ashwagandha supplements in the literature, though causality and the specific role of withanolides versus other constituents has not been confirmed.

### What foods or plants other than ashwagandha contain withanolides?

While Withania somnifera is the primary commercial source, withanolides have also been isolated from other Solanaceae family members including Withania coagulans, Physalis peruviana (cape gooseberry), and Dunalia spinosa. However, withanolide concentrations in these alternative sources are substantially lower than in W. somnifera root, and no standardized supplements derived from these plants are currently validated in clinical trials.

### How do withanolides get absorbed and metabolized in the body?

Withanolides are lipophilic compounds that require dietary fat for optimal absorption in the gastrointestinal tract, which is why ashwagandha supplements are often recommended with meals. Once absorbed, withanolides undergo hepatic metabolism and are distributed throughout the body, though research on their specific metabolic pathways and bioavailability rates in humans remains limited. The presence of food and individual digestive health can significantly affect how much withanolide reaches systemic circulation from a supplement dose.

### Why do different ashwagandha extracts have varying withanolide concentrations?

Withanolide content varies based on plant part used (root vs. leaf), growing conditions, harvest timing, and extraction methods employed by manufacturers. Over 300 distinct withanolide variants exist in ashwagandha, and different extraction processes preferentially concentrate certain compounds while leaving others behind. Standardized extracts specifically target and concentrate withanolide A, D, and other major variants, resulting in higher and more consistent potency compared to whole-plant powders.

### Are withanolides produced naturally in the plant or created during supplement processing?

Withanolides are naturally produced in ashwagandha plants through the mevalonate biosynthetic pathway as part of the plant's normal biochemistry. They are not created during supplement manufacturing, though extraction and processing methods can concentrate, isolate, or alter their ratios and bioavailability. The withanolide profile in a finished supplement reflects both the original plant material composition and any standardization or concentration techniques applied during production.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*